These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

225 related items for PubMed ID: 5472041

  • 1. [Two years experience with L-DOPA in association with a decarboxylase inhibitor].
    Siegfried J.
    Rev Neurol (Paris); 1970 Apr; 122(4):243-8. PubMed ID: 5472041
    [No Abstract] [Full Text] [Related]

  • 2. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R, Gaillard JM, Guggisberg M, Gauthier G, de Ajuriaguerra J.
    Presse Med (1893); 1969 Apr 05; 77(17):619-22. PubMed ID: 5785081
    [No Abstract] [Full Text] [Related]

  • 3. Therapeutic uses and side effects of L-dopa.
    Boshes B.
    Adv Intern Med; 1972 Apr 05; 18():219-49. PubMed ID: 4576081
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.
    Barbeau A, Mars H, Botez MI, Joubert M.
    Can Med Assoc J; 1972 Jun 10; 106(11):1169-74. PubMed ID: 5034697
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor].
    Christiani K, Möller WD.
    Munch Med Wochenschr; 1973 Apr 20; 115(16):711-3. PubMed ID: 4197759
    [No Abstract] [Full Text] [Related]

  • 11. [L-DOPA with the decarboxylase inhibitor Ro 4-4602 in the treatment of Parkinson's disease].
    Lakke JP, Nienhuis RJ, Meyer R, Zwols F, Schut T.
    Ned Tijdschr Geneeskd; 1972 Nov 25; 116(48):2180-4. PubMed ID: 4639072
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N, Kito S, Yamamoto M, Itoga E, Kosaka K.
    Nihon Rinsho; 1974 Mar 25; 32(3):579-86. PubMed ID: 4859014
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E, Mårtensson A.
    Scand J Rehabil Med; 1974 Mar 25; 6(2):89-93. PubMed ID: 4837060
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Side effects of L-dopa treatment.
    Greenburg J.
    Pa Med; 1971 Apr 25; 74(4):55-6. PubMed ID: 5147645
    [No Abstract] [Full Text] [Related]

  • 20. L-Dopa, B 6 , and alpha-methyldopa hydrazine.
    Klawans HL, Ringel SP.
    Confin Neurol; 1973 Apr 25; 35(3):186-92. PubMed ID: 4712885
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.